FY2029 Earnings Forecast for Q32 Bio Issued By HC Wainwright

Q32 Bio Inc. (NASDAQ:QTTB) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Q32 Bio in a report released on Wednesday, February 25th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of ($0.18) per share for the year. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.32) per share. HC Wainwright also issued estimates for Q32 Bio’s FY2030 earnings at $0.11 EPS.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Q32 Bio in a research report on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $14.00.

Q32 Bio Stock Performance

Shares of QTTB stock opened at $4.56 on Thursday. The stock has a fifty day moving average price of $3.81 and a 200 day moving average price of $2.90. The stock has a market cap of $56.11 million, a PE ratio of -1.33 and a beta of 0.16. Q32 Bio has a 1 year low of $1.35 and a 1 year high of $6.37.

Institutional Investors Weigh In On Q32 Bio

Hedge funds have recently made changes to their positions in the business. Marshall Wace LLP purchased a new stake in shares of Q32 Bio in the second quarter valued at $25,000. ADAR1 Capital Management LLC acquired a new stake in Q32 Bio in the 4th quarter worth about $66,000. XTX Topco Ltd purchased a new stake in Q32 Bio in the 4th quarter valued at about $68,000. HRT Financial LP grew its holdings in Q32 Bio by 66.5% in the 4th quarter. HRT Financial LP now owns 24,698 shares of the company’s stock valued at $81,000 after buying an additional 9,862 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of Q32 Bio during the 4th quarter valued at about $84,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

Insider Buying and Selling at Q32 Bio

In other Q32 Bio news, CFO Lee Kalowski sold 9,072 shares of the firm’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $3.46, for a total transaction of $31,389.12. Following the completion of the transaction, the chief financial officer owned 39,938 shares of the company’s stock, valued at approximately $138,185.48. This trade represents a 18.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Jodie Pope Morrison sold 22,506 shares of the business’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $3.46, for a total value of $77,870.76. Following the completion of the transaction, the chief executive officer directly owned 99,000 shares of the company’s stock, valued at approximately $342,540. This trade represents a 18.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 48,284 shares of company stock valued at $184,604 in the last three months. 40.00% of the stock is currently owned by company insiders.

Trending Headlines about Q32 Bio

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, providing a long‑term constructive view that can support upside versus current levels. HC Wainwright Begins Coverage on Q32 Bio
• Neutral Sentiment: HC Wainwright published a multi‑year forecast showing improving EPS over time and an eventual transition to modest profitability in FY2030 (EPS $0.11), which is a positive directional signal but depends on successful clinical and commercial execution.
• Negative Sentiment: The analyst model shows substantial near‑term losses: Q4 2025 EPS of ($0.63) and FY2025–FY2028 EPS ranging from about ($2.91) to ($2.19). These projected deficits increase financing and execution risk and likely weigh on short‑term investor sentiment.
• Negative Sentiment: Consensus full‑year earnings remain deeply negative (current consensus ~($12.32) per share), indicating the market and other analysts expect much larger near‑term losses than HC Wainwright’s more optimistic runway—this divergence may temper the impact of the Buy rating.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.